These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 32839459)
1. Integration of postmortem amygdala expression profiling, GWAS, and functional cell culture assays: neuroticism-associated synaptic vesicle glycoprotein 2A (SV2A) gene is regulated by miR-133a and miR-218. Jurkiewicz M; Moser D; Koller A; Yu L; Chen EI; Bennett DA; Canli T Transl Psychiatry; 2020 Aug; 10(1):297. PubMed ID: 32839459 [TBL] [Abstract][Full Text] [Related]
2. Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein. Gillard M; Chatelain P; Fuks B Eur J Pharmacol; 2006 Apr; 536(1-2):102-8. PubMed ID: 16556440 [TBL] [Abstract][Full Text] [Related]
3. Synaptic vesicle protein2A decreases in amygdaloid-kindling pharmcoresistant epileptic rats. Shi J; Zhou F; Wang LK; Wu GF J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):716-722. PubMed ID: 26489628 [TBL] [Abstract][Full Text] [Related]
4. MicroRNA regulation of homeostatic synaptic plasticity. Cohen JE; Lee PR; Chen S; Li W; Fields RD Proc Natl Acad Sci U S A; 2011 Jul; 108(28):11650-5. PubMed ID: 21697510 [TBL] [Abstract][Full Text] [Related]
5. Synaptic Vesicle Glycoprotein 2A Is Affected in the Central Nervous System of Mice with Huntington Disease and in the Brain of a Human with Huntington Disease Postmortem. Bertoglio D; Verhaeghe J; Wyffels L; Miranda A; Stroobants S; Mrzljak L; Dominguez C; Skinbjerg M; Bard J; Liu L; Munoz-Sanjuan I; Staelens S J Nucl Med; 2022 Jun; 63(6):942-947. PubMed ID: 34531262 [TBL] [Abstract][Full Text] [Related]
6. Homozygous Mutation in Synaptic Vesicle Glycoprotein 2A Gene Results in Intractable Epilepsy, Involuntary Movements, Microcephaly, and Developmental and Growth Retardation. Serajee FJ; Huq AM Pediatr Neurol; 2015 Jun; 52(6):642-6.e1. PubMed ID: 26002053 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic Role of Synaptic Vesicle Glycoprotein 2A (SV2A) in Modulating Epileptogenesis. Ohno Y; Tokudome K CNS Neurol Disord Drug Targets; 2017; 16(4):463-471. PubMed ID: 28393712 [TBL] [Abstract][Full Text] [Related]
8. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Lynch BA; Lambeng N; Nocka K; Kensel-Hammes P; Bajjalieh SM; Matagne A; Fuks B Proc Natl Acad Sci U S A; 2004 Jun; 101(26):9861-6. PubMed ID: 15210974 [TBL] [Abstract][Full Text] [Related]
9. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Kaminski RM; Gillard M; Leclercq K; Hanon E; Lorent G; Dassesse D; Matagne A; Klitgaard H Epilepsia; 2009 Jul; 50(7):1729-40. PubMed ID: 19486357 [TBL] [Abstract][Full Text] [Related]
11. Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Wood MD; Gillard M Epilepsia; 2017 Feb; 58(2):255-262. PubMed ID: 28012162 [TBL] [Abstract][Full Text] [Related]
12. [Function of synaptic vesicle protein 2A (SV2A) as a novel therapeutic target for epilepsy]. Tokudome K; Shimizu S; Serikawa T; Ohno Y Nihon Yakurigaku Zasshi; 2018; 152(6):275-280. PubMed ID: 30531097 [TBL] [Abstract][Full Text] [Related]
13. Expression profile of synaptic vesicle glycoprotein 2A, B, and C paralogues in temporal neocortex tissue from patients with temporal lobe epilepsy (TLE). Pazarlar BA; Aripaka SS; Petukhov V; Pinborg L; Khodosevich K; Mikkelsen JD Mol Brain; 2022 May; 15(1):45. PubMed ID: 35578248 [TBL] [Abstract][Full Text] [Related]
14. No major role of common SV2A variation for predisposition or levetiracetam response in epilepsy. Lynch JM; Tate SK; Kinirons P; Weale ME; Cavalleri GL; Depondt C; Murphy K; O'Rourke D; Doherty CP; Shianna KV; Wood NW; Sander JW; Delanty N; Goldstein DB; Sisodiya SM Epilepsy Res; 2009 Jan; 83(1):44-51. PubMed ID: 18977120 [TBL] [Abstract][Full Text] [Related]
15. Amygdala-Based Altered miRNome and Epigenetic Contribution of miR-128-3p in Conferring Susceptibility to Depression-Like Behavior via Wnt Signaling. Roy B; Dunbar M; Agrawal J; Allen L; Dwivedi Y Int J Neuropsychopharmacol; 2020 Apr; 23(3):165-177. PubMed ID: 32173733 [TBL] [Abstract][Full Text] [Related]
16. Levetiracetam-induced a new seizure type in a girl with a novel SV2A gene mutation. Wang D; Zhou Q; Ren L; Lin Y; Gao L; Du J; Wang Y Clin Neurol Neurosurg; 2019 Jun; 181():64-66. PubMed ID: 31005049 [TBL] [Abstract][Full Text] [Related]
17. Analysis of Differential Expression of Synaptic Vesicle Protein 2A in the Adult Rat Brain. Mendoza-Torreblanca JG; García-Cruz ME; Sánchez-Cruz I; Gomez-Gonzalez B; Juárez-Méndez S; Gómez-Lira G Neuroscience; 2019 Nov; 419():108-120. PubMed ID: 31520710 [TBL] [Abstract][Full Text] [Related]
18. A single dose of cocaine raises SV2A density in hippocampus of adolescent rats. Rossi R; Bærentzen SL; Thomsen MB; Real CC; Wegener G; Grassi-Oliveira R; Gjedde A; Landau AM Acta Neuropsychiatr; 2024 Apr; 36(2):109-117. PubMed ID: 36847240 [TBL] [Abstract][Full Text] [Related]
19. Amyloid beta a4 precursor protein-binding family B member 1 (FE65) interactomics revealed synaptic vesicle glycoprotein 2A (SV2A) and sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) as new binding proteins in the human brain. Nensa FM; Neumann MH; Schrötter A; Przyborski A; Mastalski T; Susdalzew S; Looβe C; Helling S; El Magraoui F; Erdmann R; Meyer HE; Uszkoreit J; Eisenacher M; Suh J; Guénette SY; Röhner N; Kögel D; Theiss C; Marcus K; Müller T Mol Cell Proteomics; 2014 Feb; 13(2):475-88. PubMed ID: 24284412 [TBL] [Abstract][Full Text] [Related]
20. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond. Löscher W; Gillard M; Sands ZA; Kaminski RM; Klitgaard H CNS Drugs; 2016 Nov; 30(11):1055-1077. PubMed ID: 27752944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]